

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 15, 2024

JJ012

RRID:CVCL_D605

Type: Cell Line

Proper Citation

(RRID:CVCL_D605)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_D605

Proper Citation: (RRID:CVCL_D605)

Description: Cell line JJ012 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:8689637](#), [PMID:10906887](#), [PMID:12168675](#), [PMID:12354749](#), [PMID:19787792](#), [PMID:22057234](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26368816](#), [PMID:26589293](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: SNP array analysis.

Category: Cancer cell line

Name: JJ012

Synonyms: JJ012, JJ

Cross References: BTO:BTO:0005168, EFO:EFO_0006604, ArrayExpress:E-MTAB-2706, BioSample:SAMN03470880, cancercellines:CVCL_D605, Cosmic:1602476, Cosmic:1992323, EGA:EGAS00001000610, GEO:GSM1676351, GEO:GSM1701681, IARC_TP53:27035, Pharmacodb:JJ012_705_2019, Wikidata:Q54898950

ID: CVCL_D605

Ratings and Alerts

No rating or validation information has been found for JJ012.

No alerts have been found for JJ012.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Suh J, et al. (2024) Decoupling NAD⁺ metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2 α axis. Cell reports. Medicine, 5(1), 101342.

Lin ZS, et al. (2023) EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression. eLife, 12.

Bernardo-Bermejo S, et al. (2023) Quantitative multiple fragment monitoring with enhanced in-source fragmentation/annotation mass spectrometry. Nature protocols, 18(4), 1296.

Pathmanapan S, et al. (2023) Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation. Cell reports, 42(6), 112578.

Nakagawa M, et al. (2022) Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma. Journal of bone oncology, 34, 100430.